Joe Rabin, Editor

About the Author Joe Rabin, Editor

Joe is an intern at Smarter Analyst. He has written on a broad range of topics, including: financial trading, career development, cybersecurity, gamification, network access control, recreation and more.

Rosenblatt Sets Bullish Expectations on Oracle Corporation (ORCL) Ahead of F1Q18 Print

ORCL’s ability to show improving margins is key for short-term success, says analyst.

Read more

Here’s Why You Should Buy SAGE Therapeutics Inc (SAGE) Following Failure of SRSE Drug

J.P. Morgan believes key upcoming trials could boost investor sentiment.

Read more

Is New Teva Pharmaceutical Industries Ltd (ADR) (TEVA) CEO Walking into a Landmine? Oppenheimer and Maxim Weigh In

Here’s why analysts are playing it cautiously optimistic on the struggling pharmaceutical giant.

Read more

Rexahn Pharmaceuticals, Inc. (RNN) Phase 2a Update in Muscle Invasive Bladder Cancer Shows Promise, Cheers H.C. Wainwright

RNN’s Phase 2a results have analyst optimistic on RX-3117 drug for patients running out of options.

Read more

Cowen Positive on Sarepta Therapeutics Inc (SRPT) Following Successful Early-Stage DMD Trial

Analyst upbeat on boosted dystrophin expression levels in Sarepta’s lead candidate golodirsen.

Read more

William Blair Sees Limited Downside Potential for Finisar Corporation (FNSR) in Light of Setback in 3-D Production

Strong datacom market drivers could spur revenue growth in second half of fiscal 2018, says analyst.

Read more

FuelCell Energy Inc (FCEL) Project Bookings Are Primary Catalysts for Growth: Roth Capital

Analyst sees $800 million in contract revenue potential for FuelCell.

Read more

Activision Blizzard, Inc. (ATVI) Destiny 2 Launch Could Provide Upside: Piper Jaffray

Top analyst takes note that Activision eyes Asian market with October PC release of newest video game.

Read more

Cowen Sees High 80% Probability of FDA Approval for Insmed Incorporated’s (INSM) NTM Drug

Insmed’s lead asset ALIS poses compelling prospects for commercial success in the U.S., says top analyst.

Read more

Cowen Shares Key Insights on Gilead Sciences, Inc. (GILD) Following Management Meetings

Gilead is very confident on the successful commercial launch of Axi-Cel.

Read more